logo-loader

XPhyto Therapeutics provides update on their oral film drug delivery platform with Vektor Pharma

Published: 13:25 24 Sep 2020 EDT

XPhyto Therapeutics (CSE: XPHY-OTC: XPHYF) CEO Hugh Rogers joined Steve Darling from Proactive to provide a look at their German subsidiary, Vektor Pharma who is currently advancing two sublingual ODF development programs for the delivery of the active pharmaceutical ingredients.

Rogers telling Proactive the program is on track and a European human study for its sublingual CBD product is planned for Q1 2021 with results expected in Q2 2021.

Novo Resources sees substantial upside potential at Nunyerry

Novo Resources Corp (TSX:NVO, OTCQX:NSRPF, ASX:NVO) co-chair and acting CEO Mike Spreadborough joins Jonathan Jackson in the Proactive studio to discuss promising gold outcomes from recent reanalysis of drill intercepts in a 2023 program at Nunyerry North in Western Australia. Using advanced...

7 hours, 14 minutes ago